Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease | Canada Hyperbarics Skip to main content
Case Report Future Sci OA 2015

Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease

Agrawal G, Borody T, Turner R, Leis S, Campbell J — Future Sci OA, 2015

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers treated nine patients with difficult-to-heal Crohn's disease fistulas using a combination of infliximab, 18-30 sessions of hyperbaric oxygen therapy, and anti-MAP antibiotics.

What They Found

All nine patients (100%) experienced complete healing of their fistulas. This healing occurred within 6 to 28 weeks, and patients were followed for an average of 18 months.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The main limitation of this study is its small size, as it only involved nine patients in a case series.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Case Report
Category Wound Care
Source Pubmed
PubMed ID 28031926
Year Published 2015
Journal Future Sci OA

Cite This Study

Share

This study relates to Problem Wounds. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Wound Care

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 17, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology